Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27268470
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Expert+Opin+Drug+Saf
2016 ; 15
(9
): 1239-57
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Cardiovascular effects of anti-diabetes drugs
#MMPMID27268470
Younk LM
; Lamos EM
; Davis SN
Expert Opin Drug Saf
2016[Sep]; 15
(9
): 1239-57
PMID27268470
show ga
INTRODUCTION: Cardiovascular disease remains the major contributor to morbidity
and mortality in diabetes. From the need to reduce cardiovascular risk in
diabetes and to ensure that such risk is not exacerbated by drug treatments,
governmental regulators and drug manufacturers have focused on clinical trials
evaluating cardiovascular outcomes. AREAS COVERED: Findings from mechanistic and
clinical trials of biguanides, sulfonylureas, thiazolidinediones, dipeptidyl
peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor
agonists, and sodium-glucose co-transporter 2 (SGLT-2) inhibitors will be
reviewed. These drug classes will be compared within the context of available
cardiovascular outcomes data. Clinical implications of new study regulations will
be examined. EXPERT OPINION: Recent cardiovascular studies provide a more
comprehensive evaluation of specific anti-diabetes therapy in individuals with
high cardiovascular risk. Long-term effects of anti-hyperglycemic agents in
patients with lower cardiovascular risk are still speculative. Historical data
supports continued use of metformin as a first-line agent. DPP-4 inhibitors and
GLP-1 receptor agonists appear to have neutral effects on cardiovascular
outcomes. The significantly decreased cardiovascular risk associated with
empagliflozin SGLT-2 inhibitor therapy is impressive and may change how
practitioners prescribe add-on therapy to metformin.
|Animals
[MESH]
|Cardiovascular Diseases/etiology/*prevention & control
[MESH]
|Clinical Trials as Topic
[MESH]
|Diabetes Complications/*prevention & control
[MESH]
free
free
free
